Oncolytics Biotech Inc. announces positive interim results from the Phase 1/2 GOBLET trial evaluating the combination of perolep and atezolizumab in second-line patients with unresectable anal canal squamous cell carcinoma, led by Dirk Arnold, MD. It was announced that it was announced. Director of the Asklepios Oncology Center in Hamburg and principal investigator of the GOBLET trial, said this in an oral presentation at the 2nd International Multidisciplinary Congress on Anal Cancer (IMACC) 2023 in Rome, Italy. Ta. The positive interim data from the phase 2 GOBLET anal cancer cohort presented at the IMACC meeting is very exciting for the company and suggests the potential of perolep in gastrointestinal cancer. These results met prespecified success criteria for the cohort and exceeded previous control results in similar patient populations (1-7).
← PREVIOUS ARTICLE
Diagnostic Accuracy of Hyperbilirubinemia in Predicting Cureus Appendicitis and Appendiceal Perforation Background All diagnostic tools that can help identify appendicitis are of great importance to the emergency general surgeon.
NEXT ARTICLE →
CureusBeyond the Horizon: Revealing the Frontiers of Rectal Cancer Research and Treatment Colorectal cancer ranks as one of the most common causes of cancer-related deaths and is a major health threat worldwide. There are growing concerns about the above.